Integra LifeSciences Holdings Corporation Stock News

Integra Lifesciences Holdings Corp (NASDAQ:IART) cut its 2026 revenue and adjusted earnings guidance after July flooding disrupted operations in Cincinnati, despite expectations for strong cash generation. The medical technology company now forecasts annual revenue of $1.634 billion to $1.654 billion, down from $1.654 billion to $1.695 billion.

PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance.

PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of a proposed $600 million seven-year Senior Secured Term Loan B as part of a broader refinancing transaction.

Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients

Company to feature surgeon-led educational programming and technologies supporting liver surgery Company to feature surgeon-led educational programming and technologies supporting liver surgery

PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026.

Kirlew will lead Integra's global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution. Kirlew will lead Integra's global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution.